This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

RituxME

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

RituxME is a clinical trial of the rituximab ME/CFS research group at the Dept. of Oncology and Medical Physics at Haukeland University Hospital, Bergen, Norway. Senior Consultant Øystein Fluge and Professor Olav Mella are the study supervisors.[1] The final study, published in 2019, showed no overall improvement.[2]

Notable studies[edit | edit source]

Evidence[edit | edit source]

A substudy showing improvement in post-occlusive reactive hyperemia (PORH) but not Flow-Mediated Dilation (FMD) after 18 months rituximab, no changes in symptoms

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]